TissuBond™ Bioabsorbable Surgical Tissue Adhesive Supported by $1.6M in NSF Funding
$1.6M
Non-dilutive funding awarded
Founded in 2003, Bezwada Biomedical is pioneering a novel polymer platform that uses hard segment chemistry to create fully absorbable polyurethanes—materials engineered to degrade into biocompatible byproducts while delivering tunable performance and the strength required for surgical tissue adhesion. Its lead product, TissuBond™, is designed to transform the closure of internal and external surgical wounds.
In 2018, Bezwada partnered with EGC to define and execute a targeted non-dilutive funding strategy, aligning the program with the most competitive funding pathways. With EGC’s support, the company secured an NSF Phase I SBIR award in 2019 to advance proof-of-concept studies, followed by an NSF Phase II SBIR award. These awards then led to Bezwada successfully competing for the NSF Technology Enhancement for Commercial Partnerships (TECP) to complete device validation and FDA-required assessments needed for product commercialization.
Funding Sources
